An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2014
At a glance
- Drugs Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 18 Apr 2012 Planned number of patients changed from 60 to 68 as reported by European Clinical Trials Database record.
- 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.